See video featuring patient advocates and CCS researchers |
See more:
See video featuring patient advocates and CCS researchers |
See more:
Adj A/Prof Charles Pilgrim and Prof Andrew Spencer describe their newly funded MRFF research and how it will help patients. |
As part of Rare Disease Day today, we asked two CCS researchers - Charles Pilgrim from the Department of Surgery, and Andrew Spencer from the Australian Centre for Blood Diseases - working with rare diseases about the research being funded.
|
Researchers from the Neuroimmunology, Neurology, Neuroinflammation Laboratory led by Dr Mastura Monif in the Department of Neuroscience have identified electroclinical biomarkers that differentiate one particular type of autoimmune encephalitis (AE), known as N-methyl D-aspartate receptor (NMDAR) antibody-associated encephalitis (anti-NMDAR) from other subtypes of AE.
AE is a brain inflammation disorder caused by antibodies. A person’s immune system mistakenly targets different proteins in their brain causing damage and inflammation. This can result in different neurological symptoms including seizures and memory problems. AE can be classified into different subtypes based on the brain protein targeted by the antibodies produced.